Skip to main content
SpringerLink
Log in

The efficacy of low-dose mycophenolate mofetil for treatment of lupus nephritis in Taiwanese patients with systemic lupus erythematosus

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Mycophenolate mofetil (MMF) has recently been introduced as an immunosuppressive agent for the treatment of glomerulonephritis with systemic lupus erythematosus (SLE) and the data have been encouraging. However, response to MMF treatment appears to differ ethnically. Therefore, we determined efficacy and safety of low-dose MMF for Taiwanese patients with lupus nephritis. We studied 36 lupus nephritis patients who were treated with MMF. The dose started at 0.5 g/day and we collected the data from patients who received up to 1 g/day MMF. Outcome measures were 24 h for proteinuria, serum creatinine, C3/C4 levels, and anti-dsDNA titers collected at the baseline and at 3-month treatment intervals. Daily urinary protein significantly decreased from 6.15 ± 4.28 g to 2.69 ± 2.36 g at the last visit (P < 0.01) in spite of the significant absence of changes in serum creatinine levels. The response rate was 65.7% including five (14.3%) cases of complete remission and 18 (51.4%) cases of partial remission. The concomitant oral prednisolone dose decreased significantly from 20.07 ± 11.78 mg/day to 13.93 ± 6.79 mg/day at 6 months (P < 0.01). The level of C3 increased significantly from 59.46 ± 32.73 to 71.99 ± 25.81 (P < 0.01) and the anti-dsDNA antibody titer decreased from 161.71 ± 221.42 to 46.57 ± 117.47 (P < 0.01). No severe adverse effects were observed in the study. Low-dose MMF (0.5 to 1 g/day) combined with glucocorticoids appears to be a safe and effective therapy for lupus nephritis in Taiwanese patients. Our results suggest that lupus nephritis in Oriental patients might respond to lower doses of MMF than Caucasians.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Gladman DD, Urowitz MB (2002) Prognosis, mortality and morbidity in systemic lupus erythematosus. In: Wallace DJ, Hahn BH (eds) Dubois’ lupus erythematosus, 6th edn. Lippincott, Williams and Wilkins, Philadelphia, pp 1255–1273

    Google Scholar 

  2. Yee CS, Gordon C, Dostal C et al (2004) EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis 63:525–529

    Article  CAS  PubMed  Google Scholar 

  3. Falk RJ (2000) Treatment of lupus nephritis—a work in progress. N Engl J Med 343:1182–1183

    Article  CAS  PubMed  Google Scholar 

  4. Gourley MF, Austin HA III, Scott D et al (1996) Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial. Ann Intern Med 125:549–557

    CAS  PubMed  Google Scholar 

  5. Korbet SM, Lewis EJ, Schwartz MM et al (2000) Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis 35:904–914

    Article  CAS  PubMed  Google Scholar 

  6. Mok CC, Yee KY, Sydney Tang, Leung CY et al (2004) Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 50:2559–2568

    Article  PubMed  CAS  Google Scholar 

  7. Ioannidis JPA, Boki KA, Katsorida EM et al (2000) Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 57:258–264

    Article  CAS  PubMed  Google Scholar 

  8. Austin H, Klippel J, Balow J et al (1986) Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314:614–619

    Article  PubMed  Google Scholar 

  9. Valeri A, Radhakrishnan J, Estes D et al (1994) Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study. Clin Nephrol 42:71–78

    CAS  PubMed  Google Scholar 

  10. Boumpas DT, Austin HA III, vaughn EM et al (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741–745

    Article  CAS  PubMed  Google Scholar 

  11. Eugui EM, Allison AC (1993) Immunosuppressive activity of mycophenolate mofetil. Ann NY Acad Sci 685:309–329

    Article  CAS  PubMed  Google Scholar 

  12. Allison AC, Eugui EM (2000) Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47:85–118

    Article  CAS  PubMed  Google Scholar 

  13. Borba EF, Guedes LK, Christmann RB et al (2006) Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria. Rheumatol Int 26:1078–1083

    Article  CAS  PubMed  Google Scholar 

  14. Chan TM, Li FK, Tang CSO et al (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 343:1156–1162

    Article  CAS  PubMed  Google Scholar 

  15. Chan TM, Tse KC, Tang CSO, Mok MY et al (2005) Hong Kong Nephrology Study G. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 16:1076–1084

    Article  CAS  PubMed  Google Scholar 

  16. Dooley MA, Cosio FG, Nachman PH et al (1999) Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 10:833–839

    CAS  PubMed  Google Scholar 

  17. Adu D, Cross J, Jayne DR (2001) Treatment of systemic lupus erythematosus with mycophenolate mofetil. Lupus 10:203–208

    Article  CAS  PubMed  Google Scholar 

  18. Neylan JF (1997) Immunosuppressive therapy in high-risk trasplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. Transplantation 64:1277–1282

    Article  PubMed  Google Scholar 

  19. Dooley MA, Hogan S, Jennette C et al (1997) Cyclophosphamide therapy for lupus nephritis: poor renal suvival in black americans. Kidney Int 51:1188–1195

    Article  CAS  PubMed  Google Scholar 

  20. Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277

    Article  CAS  PubMed  Google Scholar 

  21. Weening JJ, D’Agati VD, Schwartz MM et al (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15:241–250

    Article  PubMed  Google Scholar 

  22. Ginzler EM, Aranow C (2005) Mycophenolate mofetil in lupus nephritis. Lupus 14:59–64

    Article  CAS  PubMed  Google Scholar 

  23. Elyan M, Ballou S (2009) The effectiveness and safety of mycophenolate mofetil in lupus nephritis. Clin Rheumatol

  24. Gaubitz M, Schorat A, Schotte H, Kern P, Domschke W (1999) Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 8:731–736

    Article  CAS  PubMed  Google Scholar 

  25. Ginzler EM, Dooley MA, Aranow C (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353:2219–2228

    Article  CAS  PubMed  Google Scholar 

  26. Cross J, Dwomoa A, Andrews P et al (2005) Mycophenolate mofetil for remission induction in severe lupus nephritis. Nephron Clin Pract 100:c92–100

    Article  CAS  PubMed  Google Scholar 

  27. Karim MY, Alba P, Cuadrado MJ et al (2002) Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology 41:876–882

    Article  CAS  PubMed  Google Scholar 

  28. Denton MD, Galvanek EG, Singh A, Sayegh MH (2001) Membranous lupus nephritis in a renal allograft: response to mycophenolate mofetil therapy. American Journal of Transplantation 1:288–292

    Article  CAS  PubMed  Google Scholar 

  29. Chan TM, Li FK, Tang CS, Wong RW et al (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 343:1156–1162

    Article  CAS  PubMed  Google Scholar 

  30. Appel GB, Contreras G, Dooley MA et al (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20:1103–1112

    Article  CAS  PubMed  Google Scholar 

  31. Zhu B, Chen N, Lin Y et al (2007) Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 22:1933–1942

    Article  CAS  PubMed  Google Scholar 

  32. Bijl M, Horst G, Bootsma H et al (2003) Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk. Ann Rheum Dis 62:534–539

    Article  CAS  PubMed  Google Scholar 

  33. Kingdon EJ, McLean AG, Psimenou E et al (2001) The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus 10:606–611

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosures

None

Author information

Authors and Affiliations

  1. Section of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, National Cheng-Kung University Medical College and Hospital, Tainan, Taiwan, Republic of China

    Meng-Yu Weng & Ming-Fei Liu

  2. Section of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, National Cheng-Kung University Medical College and Hospital, Dou-Liou Branch, Tainan, Taiwan, Republic of China

    Chia-Tse Weng

Authors
  1. Meng-Yu Weng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chia-Tse Weng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ming-Fei Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ming-Fei Liu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weng, MY., Weng, CT. & Liu, MF. The efficacy of low-dose mycophenolate mofetil for treatment of lupus nephritis in Taiwanese patients with systemic lupus erythematosus. Clin Rheumatol 29, 771–775 (2010). https://doi.org/10.1007/s10067-010-1403-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-010-1403-9

Keywords

Search

Navigation